Cyclobenzaprine Hydrochloride Tablet, Film Coated
Product Images NDC 68071-3154

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 68071-3154). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 3154 3

The given text seems to contain some product details. However, it is unclear due to several gibberish characters. The product appears to be Cyclobenzaprine HCl 10mg, and it comes in a quantity of three (#3). The remaining text includes information about the manufacturer, storage conditions, dosage instructions, and contact details for adverse reactions reporting. The lot number, GTIN, serial number, and expiration date are also mentioned.*

FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)

FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)

This is a comparison of the side effects of two doses (5mg and 10mg) of Cyclobenzaprine HCI tablets versus a placebo. The commonly reported side effects of Cyclobenzaprine HCI tablets are drowsiness, dry mouth, fatigue and headache. The table shows the percentage of patients who experienced these side effects in each group. For example, in the group taking the 5mg dose, 29% of patients experienced drowsiness, 21% experienced dry mouth, 6% experienced fatigue and 5% experienced headaches. The placebo group had a much lower incidence of side effects.*

FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)

This text appears to provide information on clinical studies and a surveillance program involving Cyclobenzaprine HClI tablets with a dosage of 10 mg. The text outlines the percentages of three potential side effects, including drowsiness at 39%, dry mouth at 2%, and dizziness at 1%. The surveillance program also highlights additional side effects, with an incidence rate of 16% for an unknown side effect, 7% for dry mouth, and 3% for drowsiness.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.